GlassScriptPhysician profile
Nimrat Bains
NPI 1093285629
$2,498.06
in general payments reported to CMS, 2019-2025
23 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $597 · 2022: $144 · 2024: $116 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165 · Travel and Lodging: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.92 |
| Travel and Lodging | $592.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,027.06 | 2022-2025 | Minimed 780g, Inceptiv |
| Novo Nordisk INC | $431.17 | 2021-2025 | Ozempic, Rybelsus |
| Insulet Corporation | $323.34 | 2024-2025 | Omnipod, Omnipod |
| Sanofi-Aventis U.S. LLC | $138.65 | 2021-2022 | |
| Lilly USA, LLC | $81.78 | 2021-2025 | Mounjaro |
| Dexcom, INC. | $55.45 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.27 | 2021-2025 | Jardiance |
| Corcept Therapeutics | $41.36 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $41.15 | 2021 | |
| Amgen INC. | $35.77 | 2021-2025 | Evenity |
| Alexion Pharmaceuticals, INC. | $35.12 | 2025 | Strensiq |
| Radius Health, INC. | $31.72 | 2025 | Tymlos |
| Cequr Corporation | $30.04 | 2025 | Cequr Simplicity |
| Endo Pharmaceuticals INC. | $28.56 | 2021 | |
| Becton, Dickinson and Company | $20.47 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $19.69 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $18.55 | 2025 | Nexletol |
| Abbott Laboratories | $17.32 | 2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $17.18 | 2025 | Recorlev |
| Ibsa Pharma INC. | $16.19 | 2025 | Flector, Licart, Tirosint |
| Bayer Healthcare Pharmaceuticals INC. | $15.13 | 2025 | |
| Clarus Therapeutics INC. | $14.87 | 2021 | |
| Antares Pharma, INC. | $14.22 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimrat Bains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.